Edward B. Garon

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

  JAMA Oncology · 2026-04-30

• Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

  Journal of Clinical Oncology · 2026-04-30

• First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study

  Clinical Cancer Research · 2026-04-10 · 1 citations

• Abstract 1605: Motif neoepitopes demonstrate immunogenic signal in CCL21-gene modified dendritic cell vaccination trial (NCT03546361)

  Cancer Research · 2026-04-03

• Abstract 6740: Selective immune activation of antigen activated T cells with STK-012, an a/b IL-2 receptor biased partial agonist, with pembrolizumab and chemotherapy in 1L PD-L1 negative non-squamous NSCLC

  Cancer Research · 2026-04-03

• Abstract 4243: Mutational-signature adjusted models reveal HLA-mediated depletion of antigenic mutations in non-small cell lung cancer (NSCLC)

  Cancer Research · 2026-04-03

• Correction: <i>cfTrack:</i> A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution

  Clinical Cancer Research · 2026-03-16

• Data from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

  2026-03-02

• Figure S5 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

  2026-03-02

• Figure S3 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

  2026-03-02

• Figure S4 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

  2026-03-02

• Figure S2 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

  2026-03-02

• Figure S1 from Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

  2026-03-02

• Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

  Nature Communications · 2026-02-05

• 127 Pembrolizumab Monotherapy for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (NSCLC): 10-Year Outcomes From Clinical Trials

  Lung Cancer · 2026-02-01

• Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma

  Cancer Research · 2025-12-09

• Supplementary Figures S1-S8 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS&lt;sup&gt;+&lt;/sup&gt; CD4&lt;sup&gt;+&lt;/sup&gt; T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

  2025-11-25

• Supplementary Tables S1-S4 from Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS&lt;sup&gt;+&lt;/sup&gt; CD4&lt;sup&gt;+&lt;/sup&gt; T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

  2025-11-25

• Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers

  ONCOLOGY · 2025-11-24

• Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer

  CHEST Journal · 2025-11-14